JUAN JOSÉ
LAHUERTA PALACIOS
Investigador hasta 2020
Hospital Universitario Son Espases
Palma, EspañaPublicaciones en colaboración con investigadores/as de Hospital Universitario Son Espases (22)
2024
-
Immunoparesis recovery in newly diagnosed transplant ineligible multiple myeloma patients, an independent prognostic factor that complements minimal residual disease
Annals of Hematology
-
Recovery of uninvolved heavy/light chain pair immunoparesis in newly diagnosed transplant-eligible myeloma patients complements the prognostic value of minimal residual disease detection
Haematologica, Vol. 109, Núm. 6, pp. 1909-1917
2023
-
Definition and Clinical Significance of the Monoclonal Gammopathy of Undetermined Significance-Like Phenotype in Patients With Monoclonal Gammopathies
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Vol. 41, Núm. 16, pp. 3019-3031
-
Large T cell clones expressing immune checkpoints increase during multiple myeloma evolution and predict treatment resistance
Nature Communications, Vol. 14, Núm. 1
2022
-
A simple score to predict early severe infections in patients with newly diagnosed multiple myeloma
Blood cancer journal, Vol. 12, Núm. 4, pp. 68
2021
-
Immunogenetic characterization of clonal plasma cells in systemic light-chain amyloidosis
Leukemia, Vol. 35, Núm. 1, pp. 245-249
-
Pomalidomide, Cyclophosphamide, and Dexamethasone for the Treatment of Relapsed/Refractory Multiple Myeloma: Real-World Analysis of the Pethema-GEM Experience
Clinical Lymphoma, Myeloma and Leukemia, Vol. 21, Núm. 6, pp. 413-420
-
Tumor cells in light-chain amyloidosis and myeloma show distinct transcriptional rewiring of normal plasma cell development
Blood, Vol. 138, Núm. 17, pp. 1583-1589
2020
-
Circulating tumor cells for comprehensive and multiregional non-invasive genetic characterization of multiple myeloma
Leukemia, Vol. 34, Núm. 11, pp. 3007-3018
2019
-
Flow cytometry for fast screening and automated risk assessment in systemic light-chain amyloidosis
Leukemia, Vol. 33, Núm. 5, pp. 1256-1267
2018
2013
-
Clinical applicability and prognostic significance of molecular response assessed by fluorescent-PCR of immunoglobulin genes in multiple myeloma: Results from a GEM/PETHEMA study
British Journal of Haematology, Vol. 163, Núm. 5, pp. 581-589
2012
-
Benefit from autologous stem cell transplantation in primary refractory myeloma? Different outcomes in progressive versus stable disease
Haematologica, Vol. 97, Núm. 4, pp. 616-621
-
Superiority of bortezomib, thalidomide, and dexamethasone (VTD) as induction pretransplantation therapy in multiple myeloma: A randomized phase 3 PETHEMA/GEM study
Blood, Vol. 120, Núm. 8, pp. 1589-1596
2011
-
Long-term prognostic significance of response in multiple myeloma after stem cell transplantation
Blood, Vol. 118, Núm. 3, pp. 529-534
2008
-
Dose-escalated CHOP and tailored intensification with IFE according to early response and followed by BEAM/autologous stem-cell transplantation in poor-risk aggressive B-cell lymphoma: A prospective study from the GEL-TAMO study group
European Journal of Haematology, Vol. 80, Núm. 3, pp. 227-235
-
Primary mediastinal large cell lymphoma (PMBL): Frontline treatment with autologous stem celltransplantation (ASCT). The GEL-TAMO experience
Hematological Oncology, Vol. 26, Núm. 3, pp. 171-178
2007
-
Tho adjusted International Prognostic Index and β-2-microglobulin predict the outcome after autologous stem cell transplantation in relapsing/refractory peripheral T-cell lymphoma
Haematologica, Vol. 92, Núm. 8, pp. 1067-1074
2004
-
Autologous stem-cell transplantation in diffuse large B-cell non-Hodgkin's lymphoma not achieving complete response after induction chemotherapy: The GEL/TAMO experience
Annals of Oncology, Vol. 15, Núm. 10, pp. 1504-1509
2003
-
High-dose chemotherapy and autologous stem cell transplantation in peripheral T-cell lymphoma: The GEL-TAMO experience
Annals of Oncology, Vol. 14, Núm. 12, pp. 1768-1775